Register for email alerts and news feeds:
This journal | BMJ Group
rss
The most recent version of this article was published on 1 March 2008

Ann Rheum Dis. Published Online First: 29 October 2007. doi:10.1136/ard.2007.076091
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism.

Extended Report

The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow edema in patients with psoriatic arthritis

A P Anandarajah 1*, E M Schwarz 2, S Totterman 3, J Monu 1, CY Feng 4, T Shao 4, S A Haas-Smith 4 and C T Ritchlin 1

1 University of Rochester Medical Center, United States
2 Center for Musculoskeletal Research, United States
3 Virtual scopics, United States
4 University of Rochester, United States

* To whom correspondence should be addressed. E-mail: allen_anandarajah{at}urmc.rochester.edu.

Accepted 13 October 2007


Abstract

Objective: The frequency of osteoclast precursors (OCPF) and the presence of bone marrow edema (BME) are potential response biomarkers in psoriatic arthritis (PsA). Previous studies suggest a central role for TNF in the formation of osteoclast precursors. To better understand this association, the effect of etanercept on OCPF and BME was analyzed in PsA patients with erosive arthritis.

Methods: Twenty PsA patients with active erosive PsA were enrolled. Etanercept was administered twice weekly for 24 weeks. OCPF was measured and clinical assessments were performed at baseline, 2, 12 and 24 weeks. Gadolinium enhanced MR images were obtained at baseline and 24 weeks.

Results: Significant improvement in joint score (p<0.001), HAQ scores (p<0.001) and SF-36 parameters, was observed after 6 months of therapy with etanercept compared to baseline. The median OCPF decreased from 24.5 to 9 (p=0.04) and 7 after 3 months and 6 months of treatment, respectively. MR images were available in 13 patients. The BME volume decreased in 47 and increased in 31 sites at 6 months. No correlation was noted between OCPF, BME and clinical parameters.

Conclusion: The rapid decline in OCPF and overall improvement in BME after anti-TNF-alpha therapy provides one mechanism to explain the anti-erosive effects of TNF blockade in PsA. Persistence of BME after etanercept treatment, despite a marked clinical response, was unexpected, and suggests ongoing subchondral inflammation or altered remodeling in PsA bone.

Keywords: MRI, bone marrow edema, etanercept, osteoclast precursors, psoriatic arthritis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • RITCHLIN, C. T., PROULX, S., SCHWARZ, E. S. (2009). Translational Perspectives on Psoriatic Arthritis. The Journal of Rheumatology Supplement 83: 30-34 [Abstract] [Full Text]  
  • CIMMINO, M. A., PARODI, M., ZAMPOGNA, G., PAPARO, F., SILVESTRI, E., GARLASCHI, G., SCARPA, R. (2009). Magnetic Resonance Imaging of the Hand in Psoriatic Arthritis. The Journal of Rheumatology Supplement 83: 39-41 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs